Claudia Styslinger | IR |
Geraldine Henwood | President & CEO |
Ryan Lake | CFO |
Leland Gershell | Oppenheimer & Co. |
Michael Ingerman | Piper Jaffray & Co. |
David Amsellem | Piper Jaffray |
Iris Long | Berenberg Capital Markets |
Good morning, and welcome to the Recro Pharma Second Quarter 2019 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded at the company's request.
I would now like to turn the call over to Claudia Styslinger, Investor Relations.
You may begin.
Good morning, and thank you for joining us on today's conference call to discuss Recro's second quarter 2019 financial results.